Amphastar Pharmaceuticals (AMPH) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Amphastar Pharmaceuticals (NASDAQ: AMPH) in the last few weeks:

• 8/18/2026 – Amphastar Pharmaceuticals had its price target raised by Barclays PLC from $20.00 to $23.00. They now have an “equal weight” rating on the stock.
• 8/8/2026 – Amphastar Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 8/7/2026 – Amphastar Pharmaceuticals had its price target lowered by Piper Sandler from $21.00 to $20.00. They now have a “neutral” rating on the stock.
• 8/7/2026 – Amphastar Pharmaceuticals had its price target raised by Wells Fargo & Company from $19.00 to $20.00. They now have an “equal weight” rating on the stock.
• 7/21/2026 – Amphastar Pharmaceuticals was upgraded by Zacks Research from “strong sell” to “hold”.
• 7/8/2026 – Amphastar Pharmaceuticals had its “sell (d+)” rating reaffirmed by Weiss Ratings.
• 6/29/2026 – Amphastar Pharmaceuticals had its “underperform” rating reaffirmed by Bank of America Corporation. They now have a $20.00 price target on the stock, down from $25.00.

Insider Activity

In other news, CFO William J. Peters sold 8,180 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $22.48, for a total value of $183,886.40. Following the completion of the transaction, the chief financial officer owned 172,846 shares in the company, valued at $3,885,578.08. This represents a 4.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard K. Prins sold 7,973 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $20.30, for a total value of $161,851.90. Following the transaction, the director owned 29,625 shares of the company’s stock, valued at approximately $601,387.50. This trade represents a 21.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 29.60% of the company’s stock.

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.